Cargando…
Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852293/ https://www.ncbi.nlm.nih.gov/pubmed/36685639 http://dx.doi.org/10.1016/j.bbih.2022.100584 |
_version_ | 1784872595944898560 |
---|---|
author | Skorobogatov, Katrien Autier, Valérie Foiselle, Marianne Richard, Jean-Romain Boukouaci, Wahid Wu, Ching-Lien Raynal, Sophie Carbonne, Christel Laukens, Kris Meysman, Pieter Coppens, Violette le Corvoisier, Philippe Barau, Caroline De Picker, Livia Morrens, Manuel Tamouza, Ryad Leboyer, Marion |
author_facet | Skorobogatov, Katrien Autier, Valérie Foiselle, Marianne Richard, Jean-Romain Boukouaci, Wahid Wu, Ching-Lien Raynal, Sophie Carbonne, Christel Laukens, Kris Meysman, Pieter Coppens, Violette le Corvoisier, Philippe Barau, Caroline De Picker, Livia Morrens, Manuel Tamouza, Ryad Leboyer, Marion |
author_sort | Skorobogatov, Katrien |
collection | PubMed |
description | Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite levels on diagnosis, clinical state, symptom severity and clinical course in a large French transdiagnostic cohort of SCZ and BD patients. Four patient groups (total n = 507) were included in a cross-sectional observational study: 1) hospitalized acute bipolar patients (n = 205); 2) stable bipolar outpatients (n = 116); 3) hospitalized acute schizophrenia patients (n = 111) and 4) stable schizophrenia outpatients (n = 75), in addition to healthy controls (HC) (n = 185). The quantitative determination of serum kynurenine metabolites was performed using liquid chromatography–tandem mass spectrometry. Kynurenine levels were lower in all patients combined compared to HC while ANCOVA analyses did not reveal inter-diagnostic difference between SCZ and BD. Interestingly, hospitalized patients of both diagnostic groups combined displayed significantly lower kynurenine levels than stabilized outpatients. Psychotic symptoms were associated with lower quinaldic acid (F = 9.18, p=<.001), which is KAT-driven, whereas a longer duration of illness contributed to abnormalities in tryptophan (F = 5.41, p = .023), kynurenine (F = 16.93, p=<.001), xanthurenic acid (F = 9.34, p = .002), quinolinic acid (F = 9.18, p = .003) and picolinic acid (F = 4.15, p = .043), metabolized through the KMO-branch. These data confirm illness state rather than diagnosis to drive KP alterations in SCZ and BD. Lower levels of KP metabolites can thus be viewed as a transdiagnostic feature of SCZ and BD, independently associated with acute symptomatology and a longer duration of illness. Quinaldic acid has seldomly been investigated by previous studies and appears an important state marker in SCZ and BD. As serum samples are used in this study, it is not possible to extrapolate these findings to the brain. |
format | Online Article Text |
id | pubmed-9852293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-98522932023-01-21 Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder Skorobogatov, Katrien Autier, Valérie Foiselle, Marianne Richard, Jean-Romain Boukouaci, Wahid Wu, Ching-Lien Raynal, Sophie Carbonne, Christel Laukens, Kris Meysman, Pieter Coppens, Violette le Corvoisier, Philippe Barau, Caroline De Picker, Livia Morrens, Manuel Tamouza, Ryad Leboyer, Marion Brain Behav Immun Health Full Length Article Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite levels on diagnosis, clinical state, symptom severity and clinical course in a large French transdiagnostic cohort of SCZ and BD patients. Four patient groups (total n = 507) were included in a cross-sectional observational study: 1) hospitalized acute bipolar patients (n = 205); 2) stable bipolar outpatients (n = 116); 3) hospitalized acute schizophrenia patients (n = 111) and 4) stable schizophrenia outpatients (n = 75), in addition to healthy controls (HC) (n = 185). The quantitative determination of serum kynurenine metabolites was performed using liquid chromatography–tandem mass spectrometry. Kynurenine levels were lower in all patients combined compared to HC while ANCOVA analyses did not reveal inter-diagnostic difference between SCZ and BD. Interestingly, hospitalized patients of both diagnostic groups combined displayed significantly lower kynurenine levels than stabilized outpatients. Psychotic symptoms were associated with lower quinaldic acid (F = 9.18, p=<.001), which is KAT-driven, whereas a longer duration of illness contributed to abnormalities in tryptophan (F = 5.41, p = .023), kynurenine (F = 16.93, p=<.001), xanthurenic acid (F = 9.34, p = .002), quinolinic acid (F = 9.18, p = .003) and picolinic acid (F = 4.15, p = .043), metabolized through the KMO-branch. These data confirm illness state rather than diagnosis to drive KP alterations in SCZ and BD. Lower levels of KP metabolites can thus be viewed as a transdiagnostic feature of SCZ and BD, independently associated with acute symptomatology and a longer duration of illness. Quinaldic acid has seldomly been investigated by previous studies and appears an important state marker in SCZ and BD. As serum samples are used in this study, it is not possible to extrapolate these findings to the brain. Elsevier 2023-01-02 /pmc/articles/PMC9852293/ /pubmed/36685639 http://dx.doi.org/10.1016/j.bbih.2022.100584 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Full Length Article Skorobogatov, Katrien Autier, Valérie Foiselle, Marianne Richard, Jean-Romain Boukouaci, Wahid Wu, Ching-Lien Raynal, Sophie Carbonne, Christel Laukens, Kris Meysman, Pieter Coppens, Violette le Corvoisier, Philippe Barau, Caroline De Picker, Livia Morrens, Manuel Tamouza, Ryad Leboyer, Marion Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
title | Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
title_full | Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
title_fullStr | Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
title_full_unstemmed | Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
title_short | Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
title_sort | kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852293/ https://www.ncbi.nlm.nih.gov/pubmed/36685639 http://dx.doi.org/10.1016/j.bbih.2022.100584 |
work_keys_str_mv | AT skorobogatovkatrien kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT autiervalerie kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT foisellemarianne kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT richardjeanromain kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT boukouaciwahid kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT wuchinglien kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT raynalsophie kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT carbonnechristel kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT laukenskris kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT meysmanpieter kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT coppensviolette kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT lecorvoisierphilippe kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT baraucaroline kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT depickerlivia kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT morrensmanuel kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT tamouzaryad kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder AT leboyermarion kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder |